Decorin
Small molecule
Decorin is one of 15 small molecule programs targeting Proliferative Vitreoretinopathy. It is currently in development.
1
Indications
2
Total Trials
0
Active Trials
14
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
15 competitors in Proliferative Vitreoretinopathy
#DrugCompanyPhaseTrials
1Colcrys
Alnylam PharmaceuticalsApproved
Accutane
CConrado Roberto Hoffmann Filho
Approved
Decadron
AAspen Global Incorporated
Approved
Heparin Sodium
BBaxter Healthcare Corporation
Approved
Adrucil
EElorac, Inc.
Approved
Kenalog
BBausch Health Americas, Inc.
Phase 3
Trexall
Alnylam PharmaceuticalsPhase 2
Intravitreal Aflibercept
RegeneronPhase 2
ADX-2191
AAldeyra Therapeutics, Inc.
Phase 3
Rhopressa
FFalcon
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
CLE1 trial
Decorin in Sub Scleral Trabeculectomy
Unknown status·—·Phase 1·NCT03924544·52 enrolled
Proliferative Vitreoretinopathy1 trial
Dacorin for Proliferative Vitreoretinopathy
Completed·—·Phase 1/2·NCT02865031·15 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Decorin. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Company
- CCairo University